This podcast is a brief review of emerging literature focusing on the potential use of GLP-1 receptor agonists in the treatment of mental health and substance use disorders. The episode explores how GLP-1 receptor agonists work to alter neurotransmitter systems and impact inflammation in the brain.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode explores the unique perspectives of pharmacy technician educators and their role in shaping the next generation of technicians. Listeners will gain insights into effective teaching strategies, current challenges in technician education, and innovative approaches to competency development.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, Dr. Ben Anderson and Dr. Mike Ganio discuss the AJHP ASHP Report "Proceedings of the ASHP Autoverification Work Group: Findings and Guidance” with host and AJHP Editor in Chief Dr. Daniel Cobaugh.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode will review the management of diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS) and euglycemic diabetic ketoacidosis (eDKA). Listeners will review the most current DKA/HHS guidelines and will be able to effective identify patients receiving insulin and fluid therapy that require changes in treatment to improve safety and disease resolution.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores how the federal government is attempting to lower prescription drug prices by examining the newest most-favored nation-focused drug pricing models, including TrumpRx and the GLOBE and GUARD mandatory models. We discuss how each model is structured and its potential impacts on patients, the healthcare system, and the pharmacy workforce.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, Megan Musselman sits down with the Section of Clinical Specialists and Scientists Distinguished Service Awardee Martha Roberts to discuss what membership within the section and ASHP means to them and how it has helped develop them into a pharmacy practice leader.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode series will focus on the identification and underlying etiologies of status epilepticus, review treatment recommendations, and compare available antiepileptic agents for the management of status epilepticus. CE for this episode expires 2 years after the date it was originally published.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, Jeff Chalmers, immediate past-chair of the ASHP Section of Pharmacy Informatics and Technology, has a discussion with Distinguished Service Awardee for 2025, Darren Ferer, to discuss his service within the section and the role ASHP has played in his development as a pharmacy practice leader.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.